- Zhang, Yichi;
- Ojalill, Marjaana;
- Boyer, Antonia;
- Chen, Xiao Lei;
- Tahon, Elise;
- Thivolle Lioux, Gaëtan;
- Xia, Marvin;
- Abbas, Maryam;
- Soylu, Halime Meryem;
- Flieder, Douglas B;
- Connolly, Denise C;
- Molinolo, Alfredo A;
- McHale, Michael T;
- Stupack, Dwayne G;
- Schlaepfer, David D
Significance
FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.